Skip to main content

Table 5 Comparison of patients’ demographic, clinical parameters, and scales according to presence of vertebral fractures

From: Evaluation of medication adherence and medication beliefs and their relation with quality of life in osteoporotic patients with and without vertebral fractures: a path analysis

 

Vertebral fracture

Test statistica

P

Yes (n = 26)

No (n = 119)

Age (year)

69 (49–84)

68 (40–89)

1462.0

0661

Body mass index (kg/m2)

30.7 (17.3–31.4)

27.6 (3–37)

1457.0

0.643

Disease duration (year)

3 (1–12)

3 (1–15)

1426.0

0.526

BMD (L1-L4) T score

− 2.7 (− 6.2 to − 0.1)

− 2.6 (− 4.8–0.7)

1321.0

0.244

BMD (femur neck) T score

− 2.6 (− 4.2 to − 0.7)

− 2.6 (− 4.4–2.8)

1392.5

0.425

MARS Total

17 (9–25)

18 (2–25)

1371.5

0.364

BMQ-Spesific necessity

2.5 (1.2–4)

2.2 (1.2–4.6)

1383.0

0.384

BMQ-Specific concerns

2.2 (1.2–3.8)

2.2 (1.2–3.4)

1219.0

0.087

BMQ-General harm

3.1 (1.8–4.3)

3.3 (1.5–4.8)

1294.0

0.181

BMQ-General overuse

2.3 (1–4.3)

2.3 (1–4.3)

1521.5

0.894

Qualeffo-41 Pain

34.1 (24.9–39.6)

27.9 (19.4–33.8)

353.5

< 0.001

Qualeffo-41 Physical function

39.5 (25.9–46.4)

24.8 (18.2–36.4)

95.5

< 0.001

Qualeffo-41 Social function

69.7 (56.4–78.8)

53.4 (44.9–69.7)

72.5

< 0.001

Qualeffo-41 General health perception

64.8 (50.9–73.9)

48.7 (40.8–68.1)

90.5

< 0.001

Qualeffo-41 Mental function

52.7 (41.6–59.8)

37.8 (29.1–56.1)

100.0

< 0.001

Qualeffo-41 Total

48.7 (38.5–57.1)

35.1 (24.6–52.1)

118.0

< 0.001

  1. P ≤ 0.05
  2. aMann-Whitney U test; median (minimum-maximum); BMD bone mineral density, MARS Medication Adherence Report Scale, BMQ Beliefs about Medicines Questionnaire, Qualeffo-41 Quality of Life Questionnaire of the European Foundation for Osteoporosis